Arizona State Retirement System Sells 872 Shares of Cencora, Inc. (NYSE:COR)

Arizona State Retirement System cut its position in Cencora, Inc. (NYSE:COR) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,596 shares of the company’s stock after selling 872 shares during the quarter. Arizona State Retirement System’s holdings in Cencora were worth $11,368,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in COR. Swedbank AB raised its holdings in Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after purchasing an additional 31,104 shares in the last quarter. Harbor Capital Advisors Inc. bought a new position in Cencora in the third quarter worth about $62,000. Amalgamated Bank raised its holdings in Cencora by 6.2% in the third quarter. Amalgamated Bank now owns 37,969 shares of the company’s stock worth $8,546,000 after purchasing an additional 2,228 shares in the last quarter. Catalina Capital Group LLC purchased a new stake in shares of Cencora during the third quarter worth about $215,000. Finally, Foster & Motley Inc. grew its stake in shares of Cencora by 1.8% during the third quarter. Foster & Motley Inc. now owns 7,593 shares of the company’s stock worth $1,709,000 after acquiring an additional 135 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 0.8 %

Cencora stock opened at $253.51 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The stock’s 50 day simple moving average is $243.79 and its two-hundred day simple moving average is $238.29. The firm has a market cap of $49.16 billion, a PE ratio of 36.06, a P/E/G ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.87%. Cencora’s dividend payout ratio is presently 31.29%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company boosted their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Evercore ISI boosted their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average price target of $277.90.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,648 shares of company stock worth $2,862,342. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.